Abnormality in the P50 auditory-evoked potential gating is an endophenotype associated with schizophrenia. Biochemical and genetic studies have suggested that the alpha 7 nicotinic acetylcholine receptor (nAChR) is involved in this sensory gating deficit. Two related alpha 7 genes (CHRNA7 and CHRNA7-like gene) resulting from a partial duplication (from exon 5 to exon 10) are present in the human genome. Two types of genetic variation, a large deletion and a −2 base-pair deletion in exon 6 resulting in a truncation of the open reading frame, affect specifically the CHRNA7-like gene. We developed a simple multiplex PCR assay on genomic DNA, allowing the quantification of the number of exons 6 and the distinction of all possible exon 6 genotypes. Genotyping of 70 schizophrenic patients and 77 controls showed that carrying at least one −2 bp deletion of exon 6 did not constitute a risk factor for schizophrenia. In contrast, the distribution of genotypes differed significantly between subjects with normal and abnormal P50 ratios, with an over-representation of genotypes carrying at least one −2 bp deletion of exon 6 among subjects exhibiting an abnormal P50 ratio. We thus conclude that the −2 bp deletion within the CHRNA7-like gene is a risk factor for P50 sensory gating deficit. Interestingly, most of the effect came from the non schizophrenic group, which may suggest that in schizophrenic patients other risk factors account for the large proportion of subjects exhibiting an abnormal P50 ratio.
Abnormality in the P50 auditory-evoked potential gating is an endophenotype associated with schizophrenia. Biochemical and genetic studies have suggested that the alpha 7 nicotinic acetylcholine receptor (nAChR) is involved in this sensory gating deficit. Two related alpha 7 genes (CHRNA7 and CHRNA7-like gene) resulting from a partial duplication (from exon 5 to exon 10) are present in the human genome. Two types of genetic variation, a large deletion and a −2 base-pair deletion in exon 6 resulting in a truncation of the open reading frame, affect specifically the CHRNA7-like gene. We developed a simple multiplex PCR assay on genomic DNA, allowing the quantification of the number of exons 6 and the distinction of all possible exon 6 genotypes. Genotyping of 70 schizophrenic patients and 77 controls showed that carrying at least one −2 bp deletion of exon 6 did not constitute a risk factor for schizophrenia. In contrast, the distribution of genotypes differed significantly between subjects with normal and abnormal P50 ratios, with an over-representation of genotypes carrying at least one −2 bp deletion of exon 6 among subjects exhibiting an abnormal P50 ratio. We thus conclude that the −2 bp deletion within the CHRNA7-like gene is a risk factor for P50 sensory gating deficit. Interestingly, most of the effect came from the non schizophrenic group, which may suggest that in schizophrenic patients other risk factors account for the large proportion of subjects exhibiting an abnormal P50 ratio. There is convincing evidence that diminished inhibitory gating of the P50 wave of the auditory-evoked response to repeated auditory stimuli reflects an inherited trait (endophenotype) predisposing to schizophrenia. Approximately 90% of schizophrenic patients and about 50% of their first-degree relatives fail to gate the auditory-evoked response to paired stimuli, compared to about 10% of normal subjects. 1, 2 A strong genetic component is likely to influence this trait since monozygotic twins have significantly higher intra-pair similarity for the P50 test/conditioning (T/C) ratio than dizygotic twins. 3 Several studies have suggested that nicotinic cholinergic dysfunction is a potential mechanism for the failure to reduce the P50 response. [4] [5] [6] Furthermore, a genome-wide linkage analysis, using P50 sensory gating deficit as phenotype, has shown that this defect was linked to a dinucleotide polymorphism on chromosome 15q13-14 where the alpha 7 nicotinic receptor subunit gene (CHRNA7) maps. 7 Two related alpha 7 genes resulting from a partial duplication and located approximately 500 kb apart are present on chromosome 15. In both genes, exons 5-10 are nearly identical. The first locus (ie CHRNA7 gene) contains specific sequences corresponding to exons 1-4 whereas, at the second locus (ie CHRNA7-like gene), these sequences are replaced by exons D, C, B and A. 8 Recently, it has been reported that in a subset of subjects the CHRNA7-like gene is missing. 9, 10 In addition, a −2 bp deletion located in exon 6 and presumably specific of the CHRNA7-like gene has also been reported. 8 To investigate the involvement of these genetic variations in an abnormal P50 inhibition, we developed a quantitative analysis of exon 6 on genomic DNA 11 which allowed us: (i) to determine in each individual the copy number of exon 6; and (ii) to discriminate exons 6 carrying the −2 bp deletion. Distributions of genotypes were then compared between schizophrenic patients and controls, and between subjects with normal and abnormal P50 phenotype. This analysis was performed in a population of 147 subjects (70 schizophrenic patients and 77 control subjects). In accordance with previous results, 91% of patients and 18% of controls had abnormal P50 T/C ratio, respectively. Exons 6 without the −2 bp deletion were counted as 'wild type' (wt) and exons 6 with the −2 bp deletion were counted as 'TG deleted' (⌬ TG). Six genotypes, corresponding to 2 wt/2 ⌬ TG, 3 wt/1 ⌬ TG, 2 wt/1 ⌬ TG, 4 wt/0 ⌬ TG, 3 wt/0 ⌬ TG and 2 wt/0 ⌬ TG ( Figure  1 and Table 1 ), were identified among the 147 subjects. Thus, in a subset of subjects, only three or, more rarely, two exons 6 were present instead of four, in accordance with the recent finding that a large deletion involving the CHRNA7-like locus is prevalent in the general population, either at the heterozygous or at the homozygous state. 9, 10 We found that, in these subjects, the Red line corresponds to the tested subject. All samples were normalized upon an external marker, ie exon 21 of ARVCF gene. The peak identified as exon 6 corresponds to the amplification of wild-type exons 6 of CHRNA7 and CHRNA7-like genes (171 bp); the arrow indicates the amplification of exon 6 carrying the ⌬TG deletion specific of CHRNA7-like gene (169 bp); the peak identified as exon 2 corresponds to the amplification of exon 2 specific of CHRNA7 gene (226 bp); the peak identified as control corresponds to the amplification of exon 21 of ARVCF gene (235 bp). Molecular Psychiatry number of exons 2, which are specific of the CHRNA7 gene, was indeed unaffected. Genotypes were then determined in six subjects from whom brain samples were available. Specific PCRamplification and sequencing of the cDNAs derived from CHRNA7 and CHRNA7-like genes, respectively, showed that the −2 bp deletion was specific of the CHRNA7-like gene, as previously suggested 8 (data not shown). Since the functional significance of the −2 bp deletion is unknown (ie gain or loss of function at the protein level), we used two different classifications to define the potential 'at risk' genotype. First, we considered 2 wt/2 ⌬ TG, 3 wt/1 ⌬ TG, 2 wt/1 ⌬ TG, 3 wt/0 ⌬ TG and 2 wt/0 ⌬ TG genotypes as 'at risk' genotype as opposed to 4 wt/0 ⌬ TG genotype. In the second classification, 2 wt/2 ⌬ TG, 3 wt/1 ⌬ TG and 2 wt/1 ⌬ TG genotypes were considered as 'at risk' as opposed to 4 wt/0 ⌬ TG, 3 wt/0 ⌬ TG and 2 wt/0 ⌬ TG genotypes. Whatever the classification used no association was detected with the schizophrenic phenotype ( 2 = 0.01, df = 1, NS, and 2 = 0.82, df = 1, NS, respectively).
We then searched for an association between the abnormal P50 ratio phenotype and the two genotypic classifications indicated above. No association was detected using the first genotypic classification ( 2 = 1.95, df = 1, NS). In contrast, when the second classification was used (ie presence of at least one −2 bp deletion, referred as '⌬ TG genotype' hereafter, as opposed to 4 wt/0 ⌬ TG, 3 wt/0 ⌬ TG and 2 wt/0 ⌬ TG genotypes, defined as 'wild-type' genotype hereafter), distributions of the two groups of genotypes were significantly different ( 2 = 6.01, df = 1, P Ͻ 0.02) between subjects with normal and abnormal P50 ratio ( Table 2 ). The corresponding odds ratio (OR) (⌬ TG genotype vs wild-type genotype) was 2.33 (95% CI = 1.18-4.62). The ⌬ TG genotype was present in 72% of subjects with abnormal P50 ratio compared to 52% of subjects with normal P50 ratio. We next dichotomized each group of subjects (ie subjects with abnormal and normal P50 ratio) according to their clinical status (schizophrenic or control subject) and compared the two classes of genotypes within each subgroup (Table  3a and b). While the two subgroups were of similar size, the association between the ⌬ TG genotype and P50 abnormality was statistically significant ( 2 = 5.24, df = 1, P Ͻ 0.03) in the controls subgroup, whereas in the schizophrenics subgroup only a slight trend was detected ( 2 = 0.23, df = 1, NS). The corresponding ORs (⌬ TG genotype vs wild-type genotype) in each subgroup were OR = 5.45 (95% CI = 1.13-26.39) and OR = 2.20, (95% CI = 0.41-11.87), respectively. However, although most of the effect detected in the entire group was contributed by the non schizophrenic subgroup, the 2 test for heterogeneity between these ORs was non significant ( 2 = 0.59, df = 1, NS). Our data support previous reports that two types of genetic variation, a large genomic deletion (as characterized in the present study by the entire exon 6 deletion) and a −2 bp deletion in exon 6 which results in a premature stop codon, affect specifically the CHRNA7-like gene. We showed that the presence of at least one -2 bp deletion (⌬ TG genotype) in the CHRNA7-like gene does not constitute a risk factor for schizophrenia by itself, but is significantly associated with P50 sensory gating deficit. Since failure to gate the P50 auditory evoked potentials is strongly associated with schizophrenia and since the del genotype is associated with this endophenotype, we should have detected in our sample an association between the ⌬ TG genotype and schizophrenia. To analyze this apparent discrepancy, the respective contribution of schizophrenic subjects and non schizophrenic controls was examined for each class of genotype and for each class of phenotype. The proportion of individuals bearing the ⌬ TG genotype and exhibiting the abnormal P50 ratio was increased in the schizophrenic subgroup as compared to that found in the control subgroup. But, simultaneously, the proportion of schizophrenic subjects without the ⌬ TG genotype who exhibited the abnormal P50 phenotype was also increased (even to a greater extent) compared to that found in controls. As a result, the association between the ⌬ TG genotype and the P50 abnormal ratio was more difficult to detect in the schizophrenic subgroup. Despite this difficulty, no significant difference in odds ratio values (OR ⌬ TG genotype vs wild-type genotype) was detected among the two subgroups by the 2 test for heterogeneity, suggesting that the ⌬ TG genotype is a risk factor for P50 abnormality, whatever the clinical status of the subject. However, we have to be cautious with this conclusion, since, given our sample size, the 2 test for heterogeneity probably lacks power to detect a true heterogeneity.
In control subjects, the probability to exhibit the P50 abnormality given the ⌬ TG genotype (ie the pen-etrance of the ⌬ TG genotype) was mild (27%) and this probability given the wild-type genotype was low (6%). In contrast, in schizophrenic patients the probability to exhibit the P50 abnormality given the ⌬ TG genotype was very high (94%) as well as the probability associated with the wild-type genotype (87%). These results suggest, first, that a protective factor (either genetic or environmental) which reduces the penetrance of the ⌬ TG genotype in controls is lacking in schizophrenic subjects. Secondly, the probability to exhibit the abnormal P50 phenotype due to another cause than the CHRNA7-like genotype abnormality is greatly increased in schizophrenic subjects. Together, these results show that the ⌬ TG genotype is a major risk factor for P50 abnormality in the general population. In schizophrenics, the intrinsic weight of this factor is lower, and other factors do share a part of responsibility in P50 abnormality. Other genetics variations, affecting either the CHRNA7-like gene or other genes in biological pathways controlling this endophenotype, are likely to be involved besides the ⌬ TG genotype.
The mechanisms by which the −2 bp deletion in exon 6 of the CHRNA7-like gene confers the risk remain to be established. However, our results argue against a loss of function of the mutant truncated protein, since in this case the statistical evidence for the association would have been greater under the genetic classification which includes the large deletion of the CHRNA7-like gene within the 'at risk' genotype. Since the converse is true, it could thus be hypothetized that the −2 bp deletion does not act by a reduction in gene dosage but generates a mutant protein acting by a gain of function or by a dominant negative effect. Specifically, we speculate that the truncated protein might affect the assembly of the alpha 7 pentamer. Alternatively, we cannot exclude that the −2 bp deletion in exon 6 of the CHRNA7-like gene might be in linkage disequilibrium with the true causative DNA polymorphism.
Materials and methods

Patients
Unrelated schizophrenic patients (51 males and 19 females, aged 38 ± 10.9 years) were included in this study. Diagnoses were made according to DSM-IIIR criteria by two trained psychiatrists after clinical interviews following the French version of the Schedule for Affective and Schizophrenia Disorders Lifetime Version (SADS-LA). A control group was composed of 37 males and 40 females, (aged 39 ± 11.7 years) free of neurological or psychiatric diseases, and who had no family history of psychosis or neurodegenerative disorders. Controls were free of any psychotropic treatment. All patients received a neuroleptic treatment but none had atypical neuroleptic medications, which, in contrast to conventional neuroleptic treatments, may normalize P50 measures. 12 All schizophrenic patients and controls were French Caucasians originating from Normandy (west part of France). Written informed conMolecular Psychiatry sent was obtained from every individual. P50 auditoryevoked potentials were recorded in all subjects.
Electrophysiological recording
Subjects were in a supine position, relaxed but awake, with head and neck well supported on pillows. They were asked to refrain from smoking for half an hour before the recording. Auditory stimuli were delivered through headphones in a conditioning-testing paradigm consisting of click pairs (S1, conditioning click; S2, testing click; 500 ms interclick interval) delivered with an interpair interval of 10 s. Clicks were produced by square wave pulse of 100 s duration and amplified to reach the intensity of 75 dB sound pressure level at the subject's ear. The subject was allowed to accommodate to the experimental situation for 5 min without recording any data. Then, three sets of 30 stimulus pairs were delivered. Electroencephalographic activity was monitored and averaged on a Nihon Kohden computer. EEG was recorded from a disk Ag/AgCl electrode affixed to the vertex (Cz, International 10-20 system), referenced to linked ears. A ground electrode was affixed on the right wrist. Horizontal and vertical electrooculograms were also recorded. Electrode impedance was less than 5000 ohms. Electrical activity was amplified with a bandpass filter of 1-200 Hz and digitized at 1000 Hz for averaging by a digital computer. All trials contaminated by ocular movements and movement artefacts were automatically rejected (criterion = 40 V). A single average was compiled from the three sets of the 30 artifact-free trials. The conditioning P50 was identified as the most positive peak between 40 and 80 ms after the first stimulus. The test P50 was identified at the same latency, plus or minus 10 milliseconds. 13 Latencies were measured as the time between stimulus onset and peak of the component. Amplitudes were measured as the difference between the peak of the P50 wave and the immediately preceding negative peak. The amplitude and the latency of the P50 wave were measured in both the conditioning and test responses. Test/conditioning ratios (T/C) were calculated by dividing the test P50 amplitude by the conditioning P50 amplitude. P50 ratios lower than 0.45 were considered as normal whereas P50 ratios higher than 0.50 indicated diminished inhibitory processing. Subjects with values between 0.45 and 0.50 were not included in the study.
Genotype analysis
To determine in each individual the number of exons 6 and to discriminate exons carrying the −2 bp deletion, we devised a multiplex PCR assay of fluorescent fragments based on the approach that we initially developed for the detection of mismatch repair gene rearrangements in hereditary non polyposis colorectal cancer 11 and which is based on: (a) the amplification of short fragments to reduce the difference of efficiency between each amplification; (b) a limited number of cycles to allow an exponential amplification; (c) the comparison of fluorescence between the same peak generated from two samples corresponding to the tested subject and to a reference subject (and not between different peaks generated from the same sample). Each sample was compared with the reference sample using an external marker to normalize the different electropherograms.
Short fragments of exon 2 of the CHRNA7 gene (sense primer: 5Ј-GGACAAGGAGCTGGTCAAGAACT-3Ј; Antisense primer: 5Ј-CTTGGGGCCAACTA-GAGTGC-3Ј; size of the amplicon: 226 bp), exons 6 of the CHRNA7 and CHRNA7-like genes (sense primer: 5Ј-GGGCATATTCAAGAGTTCCTGCTAC-3Ј; Antisense primer: 5Ј-CCACTAGGTCCCATTCTCCATTG-3Ј; size of the amplicon: 171 bp) and exon 21 of the ARVCF gene (sense primer: 5Ј-GACATGGTGCTGTGTGTG AGC-3Ј; Antisense primer: 5Ј-GGTCCGCCTTTA-GAAGTCCAAGT-3Ј; size of the amplicon: 235 bp) were simultaneously PCR-amplified using sense primers labelled with the fluorescein dye 6-FAM from 100 ng of genomic DNA extracted from peripheral blood lymphocytes using a standard proteinase K protocol. PCR was performed in a final volume of 25 l containing 0.3 M of each primer, 0.2 mM dNTP, 1.5 mM MgCl 2 , and 1 unit of Thermoprime plus Taq polymerase (Abgene, UK). After a 3 min denaturation at 95°C, the PCR consisted of 23 cycles of 15 s at 94°C, 15 s at 58°C and 15 s at 72°C followed by a final extension of 7 min at 72°C. The PCR product (1 l) was resuspended in a mix containing 2.5 l of deionised formamide, 0.5 l of GeneScan-500 Rox (PE Applied Biosystems, Warrington, UK) and 1 l of loading buffer. After denaturation for 2 min at 90°C, 2 l was loaded on a 6% denaturing polyacrylamide gel. Electrophoresis was performed for 2 h on an Applied Biosystems model 377XL automated sequencer (Applied Biosystems) with a 12 cm well to read distance, and data were analyzed using the Genescan Analysis v3.1 fluorescent fragment analyser (Applied Biosystems). The fluorescence of each peak was compared to that observed in a reference subject which has been shown to have a 2 alleles status for the ARVCF gene (data not shown). To standardize the intensity of fluorescence peaks from the tested subject relative to the reference subject, electrophoregrams were superimposed and the peaks corresponding to an external marker (ie the exon 21 of the ARVCF gene located on chromosome 22) were set to the same value.
Statistical methods
Genotypes distributions were compared using a 2 test with Yates correction if necessary. Odds ratios (OR) were calculated and compared using a chi-square test of heterogeneity, according to the Mantel-Haenszel method.
RT-PCR of the CHRNA7 and CHRNA7-like genes
Samples of frozen frontal cortex (0.5 mg) from six normal human post-mortem brains were placed in 400 l of RNA lysis buffer (Pharmacia Biotech, Uppsala, Sweden) and stored at −20°C. mRNA was extracted using the QuickPrep Micro mRNA purification kit (Pharmacia) and was resuspended into 200 l of water. Random hexamer primed cDNAs were synthesized from 20 l mRNA in a final volume of 33 l using the First-Strand cDNA Synthesis Kit (Pharmacia). CHRNA7 and CHRNA7-like cDNAs were then amplified from 5 l of the cDNA reaction using as sense primers, 5Ј-AAGGCGAGTTCCAGAGGAAG-3Ј (exon 2) and 5Ј-AAGTGGACACCTGAGTCAGCA-3Ј (exon C), respectively, and as antisense primer, 5Ј-CCAGGGAAA TCTTCTCCCCGGAA-3Ј (exon 7). PCR was performed in a final volume of 20 l containing 0.5 M of primer, 0.2 mM dNTP, 1.5 mM MgCl 2 and 1.5 units of Taq polymerase (Eurobio, Les Ulis, France). The PCR consisted of 32 cycles of 20 s at 94°C, 20 s at 55°C, and 1 min at 72°C, preceded by 3 min at 94°C and followed by 5 min at 72°C. One l of the initial PCR was then diluted in 100 l of water, and 1 l of the diluted template was submitted to a nested PCR using as sense primers, for the CHRNA7 and CHRNA7-like cDNAs, 5Ј-TCATTGTGTGTGTCAGTCTTGG-3Ј (exon 4) and 5Ј-AAATATTGCATCTACCAGCA-3Ј (exon B) respectively, and as antisense primer 5Ј-CCACTAGGTCCC ATTCTCCATTG-3Ј (exon 6). Dilution of the CHRNA7-like amplification product was amplified using a sense primer in exon B and an antisense primer in exon 6 (5Ј-CCACTAGGTCCCATTCTCCATTG-3Ј). The PCR was performed as indicated above except that the annealing temperature was 50°C. PCR products were then purified by electrophoresis on low-melt agarose gel and directly sequenced on both strands using the Big Dye Terminator Kit (Applied Biosystems) and a model 377 automated sequencer (Applied Biosystems).
